Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

"We are executing with urgency and purpose as we advance our pipeline assets to the clinic as expeditiously as possible," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "We are ...
Electronic Design

Fuzzing: What are the Latest Developments?

Explore the recent advances in fuzzing, including the challenges and opportunities it presents for high-integrity software ...
The Lancet

ChatGPT for obesity management: a review of evidence, potential challenges, and clinical implications

The global rise in the prevalence of obesity highlights the need for accessible and effective solutions for obesity ...
Virtualization Review

Expert Consultant Details How to Secure the Machine Identity Attack Surface

Sergey Chubarov explained how unmanaged non-human identities such as service accounts, API keys and tokens can become a major attack vector and outlined practical steps to improve visibility, ...
The White House

CONTINUING THE REDUCTION OF THE FEDERAL BUREAUCRACY

Section 1. Purpose. This order continues the reduction in the elements of the Federal bureaucracy that the President has determined are unnecessary. Sec. 2. Reducing the Scope of the Federal ...